Department of Health and Human Services, through National Institutes of Health, awarded Taxis Pharmaceuticals Inc of Monmouth Junction, NJ $2,000,000 under the SBIR program (Phase II), with work starting 2025-05-16 and running to 2028-04-30. It is one of 2 SBIR and STTR awards Taxis Pharmaceuticals Inc received in the last two years, $2,294,729 in all. Each figure links to the federal record.
The award
| Recipient | Taxis Pharmaceuticals Inc (Monmouth Junction, NJ) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase II |
| Amount obligated | $2,000,000 |
| Period of performance starts | 2025-05-16 |
| Period of performance ends | 2028-04-30 |
| Award number | R44AI191886 (grant, CFDA 93.855) |
| Assistance listing | 93.855, Allergy and Infectious Diseases Research |
| Place of performance | Monmouth Junction, Middlesex County, NJ |
| Recipient registry id (UEI) | C2NWS2FZS5F5 |
Want the whole picture on Taxis Pharmaceuticals Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Taxis Pharmaceuticals Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Taxis Pharmaceuticals Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
Lead optimization of oral dhfr inhibitor for the treatment of multidrug-resistant n. Gonorrhoeae infections. - abstract. The development of new antibiotics for treating n. Gonorrhoeae (ng) is lagging behind the rapid eme
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-05-26 | Continuation | 000 | $1,000,000 |
| 2025-05-16 | New | 000 | $1,000,000 |
Lead optimization of oral dhfr inhibitor for the treatment of multidrug-resistant n. Gonorrhoeae infections. - abstract. The development of new antibiotics for treating n. Gonorrhoeae (ng) is lagging behind the rapid emergence of resistant strains. Ng has developed resistance to all fda-approved therapies and even to unapproved drugs like gepotidacin and solithromycin. This highlights the scarcity of antimicrobials in clinical development, underscoring the urgent need to discover new antibacterial agents, ideally oral drugs, that can target drug-resistant ng. This SBIR phase 2 proposal presents a significant opportunity to develop a narrow-spectrum oral therapeutic for ng, where existing first-line therapies fail. Our proprietary chemical class targets bacterial dihydrofolate reductase (dhfr) and shows excellent in vitro potency, particularly against mdr ng clinical isolates. This class also boasts outstanding oral bioavailability, target selectivity, a favorable resistance profile, acceptable toxicity profile, very good pharmacokinetic (pk), and physicochemical/adme properties. While inactive against other gram-positive and gram- negative pathogens, the lead compounds TXA15054 and TXA16126 are potent against multiple ng strains, including ceftriaxone-resistant strains (who-x, who-y, who-z), and azithromycin-, ciprofloxacin-, and tetracycline-resistant CDC isolates, with impres ...
From the federal award record.
Other SBIR and STTR awards to Taxis Pharmaceuticals Inc
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2026-08-12 | Department of Health and Human Services | SBIR Phase I | $294,729 | Lead identification of oral ftsz inhibitors for the treatment of clostridioides difficile (record) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Taxis Pharmaceuticals IncLook up Taxis Pharmaceuticals Inc and see what is on record before you decide.
Get the free SnapshotWhere this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.